

## PD-L1 [E1L3N] - 149Sm





**Catalog:** 714901

**Clone:** E1L3N

**Isotype:** Rabbit IgG

**Reactivity:** Human\*

**Application:** MIBI-FFPE

**Storage:** Supplied in antibody stabilizer with 0.05% sodium azide. Store at 4°C

**IHC:** PD-L1 antibody staining of FFPE human placenta

**MIBI:** PD-L1 antibody staining (cyan) of FFPE human placenta, counterstained with dsDNA (magenta)

**IHC:** PD-L1 antibody staining of FFPE human tonsil

**MIBI:** PD-L1 antibody staining (cyan) of FFPE human tonsil, counterstained with dsDNA (magenta)

**Background**

Programmed cell death 1 ligand 1 (PD-L1, CD274) binds to PD-1 and inhibits T cell activation. APCs, activated T cells, and tissues including placenta, heart, and lung can express PD-L1. PD-L1 is expressed in cancer as a means for cancerous cells to inhibit immune responses. PD-L1 has been detected for several tumor types including melanoma, lung, ovary, colon, breast, and renal cell carcinomas. PD-L1 expression in cancer is associated with tumor infiltrating lymphocytes, which mediate PD-L1 expression through the release of interferon gamma. Inhibition of the PD-1-PD-L1 axis has been an active area of clinical research with several approved drugs for multiple indications.

**Validation**

Each lot of conjugated antibody is quality control tested by staining tissue following the MIBI Staining Protocol optimized for the applicable tissue format with subsequent MIBIScope analysis using the appropriate positive and negative tissue field of views. These results are pathologist verified.

**Recommended Usage**

Human FFPE: 1:100 dilution. For optimal results, the antibody should be titrated for each desired application.

**References**

Wimberly, H. et al. PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer. *Cancer Immunol Res.* 2015; **3**(4): 326-332.

\* Conjugate tested on human tissue.